Navigation Links
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
Date:5/7/2012

sure.

Serious adverse reactions related to the injection procedure have occurred in less than 0.1% of intravitreal injections with EYLEA including endophthalmitis, traumatic cataract, and increased intraocular pressure.

Please see the full Prescribing Information for EYLEA, available online at www.regeneron.com/EYLEA-fpi.pdf.

About Wet AMD
Age-related Macular Degeneration (AMD) is a leading cause of acquired blindness.  Macular degeneration is diagnosed as either dry (non-exudative) or wet (exudative).  In wet AMD, new blood vessels grow beneath the retina and leak blood and fluid. This leakage causes disruption and dysfunction of the retina creating blind spots in central vision, and it can account for blindness in wet AMD patients. Wet AMD is the leading cause of blindness for people over the age of 65 in the U.S. and Europe.

About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hyper
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
2. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
3. Regeneron Announces February 2012 Investor Conference Presentations
4. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
5. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
6. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
7. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
8. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
9. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
10. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
11. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... IRIDEX Corporation (Nasdaq: IRIX ) today ... ended June 28, 2014.  , Revenues were $10.6 ... $9.2 million in the 2013 second quarter and up sequentially ... for the first six months of 2014 were $20.9 million, ... of last year. , Gross margin for the quarter ...
(Date:7/31/2014)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... reported its financial results for the quarter ended June 30, ... 2014 to the same period of 2013: , Sales ... , t:slim Pump shipments grew 64 percent to 2,235 pumps ... June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25
... SAN FRANCISCO , June 22 Jennerex, Inc., ... Gregory W. Schafer as senior vice president and chief financial ... planning, investor relations and treasury functions. , ... "Greg,s finance and operations experience in the ...
... BENTONVILLE, Ark. , June 22 Walmart (NYSE: ... today they,re teaming up to provide an affordable insulin option for people with ... Beginning in mid-September, Lilly,s ... pharmacies across the U.S. under the dual-branded name Humulin ® ReliOn ...
Cached Medicine Technology:Jennerex Appoints Gregory W. Schafer as Chief Financial Officer 2Jennerex Appoints Gregory W. Schafer as Chief Financial Officer 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 2Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 3Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 4Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes 5
(Date:8/1/2014)... Lake City, UT (PRWEB) August 01, 2014 ... Medical Billing Experts, LLC (MBX) with the convergence ... Medical Professionals (BOSS), Salt Lake City, UT; Premier ... Six Seven Group (67G) of Charlotte, NC. Together ... some of the nation’s largest radiology group practices, ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 According to the ... is a comprehensive diet guide for women who want to ... list of protein rich foods and fat loss ... muscle mass. , Vkool writes in its review that this ... the truth about fat burning hormones and weight loss supplements. ...
(Date:8/1/2014)... The Journal of Neurosurgery is pleased ... the August issue entitled "Race Against the Clock: ... Hemorrhage." Authored by Peter Le Roux, MD, Charles ... and Alisa Schaefer, PhD, the 20-page supplement covers ... and methods in use for management of the ...
(Date:8/1/2014)... Millions of women suffer with lipedema, a ... some cases the arms, causing an abnormal accumulation of ... women in the U.S. alone are affected. With such ... embarrassment and discomfort caused by lipedema, it’s remarkable that ... that this is a disease,” says Dr. David Greuner, surgical ...
(Date:8/1/2014)... 2014 Register to join the webinar here: ... active years on record for life sciences investing. IPOs in ... 22 percent of all venture dollars spent in 2013. The ... valuations. , However, 2014 is proving more of a ... Silicon Valley Bank, while life sciences IPOs are losing steam, ...
Breaking Medicine News(10 mins):Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 2Health News:Three Market Leaders Come Together As One To Form A New Breed of Medical Billing Companies 3Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 2Health News:The Metabolic Switch Diet PDF Review Exposes Sally Asher's Diet Guide For Boosting Metabolism – Vkool.com 3Health News:Management of anticoagulant-associated intracerebral hemorrhage 2Health News:Management of anticoagulant-associated intracerebral hemorrhage 3Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3
... Dr. ... , and is giving patients in Texas new reasons to smile. , ... (Vocus) August 24, 2009 -- Mark Sweeney, DDS knows cosmetic dentistry… ... is director of Austin Dental Spa , a practice devoted to turning visits to the ...
... , SEATTLE, Aug. 24 Cell Therapeutics, Inc. ... and Drug Administration (FDA) has accepted and has filed for review ... relapsed or refractory aggressive non-Hodgkin,s lymphoma (NHL). A Prescription Drug User ... the review of the pixantrone NDA by September 4th 2009. ...
... Mortality remains high among patients with pulmonary arterial hypertension ... that were designed to reduce mortality and increase the ... out of University of California San Francisco. ... of the American Journal of Respiratory and Critical ...
... of Idiopathic Pulmonary Fibrosis is not much better than ... survival rate is less than three years. But ... targeting of a novel gene utilizing genetic and pharmacologic ... and will be developed for future testing in humans. ...
... ... Washington D.C. is business owner John Wahlquist of eMedicalSystems, Bremerton, Washington state. Author of his ... choice to retire his product and migrate his medical practices over to a new generation ... ...
... FAYETTE COUNTY, Ga. , Aug. 22 Dominique Wilkins, NBA ... create awareness of the fact that seniors at risk for diabetes ... provider,s office. This is the core message of the Medicare ... in Georgia since 2007 and is co-chaired nationally by the American ...
Cached Medicine News:Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 2Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 3Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 2Health News:FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone 3Health News:Still holding their breath: Mortality on lung transplant wait list remains high for some 2Health News:Still holding their breath: Mortality on lung transplant wait list remains high for some 3Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 2Health News:eMedical Systems, Inc. Selects MPMsoft as its Medical Billing Software Solution 3Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 2Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 3Health News:Dominique Wilkins Scores Big for Diabetes in Fayette County 4
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....
... hinged knee brace provides maximum ... types of sports and activities. ... rubber pads to support medial ... buttress and hyperextension stop. 3/16" ...
Medicine Products: